After COVID-19 fiasco, is there now reform happening at FDA?
On June 7, the U.S. Food and Drug Administration granted "accelerated approval" to Biogen's new Alzheimer's medication, aducanumab, two years after the company halted its first set…
On June 7, the U.S. Food and Drug Administration granted "accelerated approval" to Biogen's new Alzheimer's medication, aducanumab, two years after the company halted its first set…